This is an aggregated industry headline. Read the full story at Pharmaceutical Technology →
Sublingual semaglutide offered to UK practices despite Novo Nordisk concerns
Sublingual semaglutide, which does not hold marketing authorisation, is touted to minimise gastric issues.
By Pharmaceutical Technology
· Jul 31, 2026
· via Pharmaceutical Technology
Image: Pharmaceutical Technology
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlinePharmaceutical Technology
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
A Daiichi Sankyo quarterly report that should have celebrated strong commercial execution was instead derailed…
The WeekFierceBiotech ↗
Legend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was…
The WeekBriefing
Novartis’ Pluvicto won FDA approval on July 31 for use with ARPI therapy in PSMA-positive metastatic androgen …